• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Priveterra Acquisition Corp. II filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    5/3/24 4:01:08 PM ET
    $PMGM
    Blank Checks
    Finance
    Get the next $PMGM alert in real time by email
    false 0001821606 0001821606 2024-05-03 2024-05-03 0001821606 tmkru:UnitsEachConsistingOfOneShareOfClassaCommonStockAndOnehalfOfOneRedeemableWarrantMember 2024-05-03 2024-05-03 0001821606 us-gaap:CommonClassAMember 2024-05-03 2024-05-03 0001821606 tmkru:WarrantsEachExercisableForOneShareOfClassaCommonStockFor11.50PerShareMember 2024-05-03 2024-05-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or Section 15(d)

    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 3, 2024

     

    Priveterra Acquisition Corp. II

    (Exact name of registrant as specified in its charter)

     

    Delaware 001-39858 85-2478126
    (State or other jurisdiction of (Commission (I.R.S. Employer
    incorporation or organization) File Number) Identification Number)

     

    1 Park Plaza  
    Irvine, CA 92614
    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (949) 787-2910

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading
    Symbol(s)
      Name of each exchange
    on which registered
    Units, each consisting of one share of Class A Common Stock and one-half of one Redeemable Warrant   PMGMU   The NASDAQ Stock Market LLC
    Class A Common Stock, par value $0.0001 per share   PMGM   The NASDAQ Stock Market LLC
    Warrants, each exercisable for one share of Class A Common Stock for $11.50 per share   PMGMW   The NASDAQ Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 3.01Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

     

    As previously disclosed in the Current Report on Form 8-K filed on January 11, 2024 by Priveterra Acquisition Corp. II, a Delaware corporation (the “Company”), on January 10, 2024, the Company received a notice (the “First Notice”) from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”), the Company’s securities (common stock, warrants and units) would be subject to suspension and delisting from The Nasdaq Capital Market at the opening of business on January 19, 2024, due to the Company’s non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business combinations within 36 months of the effectiveness of its initial public offering registration statement. The Company timely requested a hearing before the Panel to allow additional time to complete a business combination. Following the hearing, the Nasdaq Hearings Panel granted the Company an exception until July 8, 2024, subject to the conditions that (i) on or before April 30, 2024, the Company shall file its Form S-4 in connection with its initial business combination and (ii) on or before July 8, 2024, the Company shall demonstrate compliance with all initial listing standards of The Nasdaq Capital Market.

     

    On April 29, 2024, the Company received an additional notice (the “Additional Notice”) from the staff of the Listing Qualifications Department of Nasdaq indicating that the Company is no longer in compliance with Nasdaq Listing Rule 5250(c)(1) since it has not yet filed its Annual Report on Form 10-K for the year ended December 31, 2023. The Additional Notice indicates that such additional delinquency may serve as a separate basis for the delisting of the Company’s securities from Nasdaq, that the Panel will consider this matter in their decision regarding the Company’s continued listing on The Nasdaq Capital Market, and that the Company should present its views with respect to this additional deficiency to the Panel in writing no later than May 6, 2024.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit
    Number
      Description
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: May 3, 2024

     
       
      PRIVETERRA ACQUISITION CORP. II
         
      By: /s/ Oleg Grodnensky
      Name:   Oleg Grodnensky
      Title: Chief Executive Officer

     

     

     

    Get the next $PMGM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PMGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PMGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Priveterra Acquisition Corp. II Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

    Priveterra Acquisition Corp. II (NASDAQ:PMGMU, PMGM, PMGMW))) (the "Company") today announced that on April 29, 2024, the Company received a notice (the "10-K Notice") from the staff of the Nasdaq Listing Qualifications department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") stating that, because the Company had not yet filed its Annual Report on Form 10-K for the period ended December 31, 2023 (the "Form 10-K"), the Company is not in compliance with Nasdaq Listing Rules for continued listing and, accordingly, such delinquency may serve as a separate basis for the delisting of the Company's securities from Nasdaq. The 10-K Notice also states that the Nasdaq Hearings Panel (the "P

    5/3/24 5:30:00 PM ET
    $PMGM
    Blank Checks
    Finance

    AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update

    Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols AEON and AEON WS, respectively Phase 2 topline data with ABP-450 for the preventive treatment of episodic migraine is anticipated to readout this fall $50 million financing provides sufficient cash runway to fund operations beyond the anticipated Phase 2 data announcement this fall IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON, AEON WS))), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, annou

    7/24/23 7:00:00 AM ET
    $PMGM
    Blank Checks
    Finance

    Priveterra Acquisition Corp. Announces Completion of Business Combination with AEON Biopharma, Inc.

    Priveterra Acquisition Corp. (NASDAQ:PMGM) ("Priveterra"), a special purpose acquisition company led by Chairman & CEO, Robert Palmisano, along with President, Vikram Malik, and COO and CFO, Oleg Grodnensky, today announced the successful completion of its business combination (the "Business Combination") with AEON Biopharma, Inc. ("AEON"), a Phase 3 stage-ready biopharmaceutical company developing a proprietary neurotoxin with initial focus on preventive treatments for episodic and chronic migraines along with other debilitating medical conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230721427813/en/ The resulting co

    7/21/23 4:27:00 PM ET
    $PMGM
    Blank Checks
    Finance

    $PMGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Thunen Shelley B

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    8/16/23 4:07:20 PM ET
    $PMGM
    Blank Checks
    Finance

    SEC Form 4 filed by Palmisano Robert J

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    8/16/23 4:06:36 PM ET
    $PMGM
    Blank Checks
    Finance

    SEC Form 4 filed by Fischer Jost

    4 - AEON Biopharma, Inc. (0001837607) (Issuer)

    8/16/23 4:06:04 PM ET
    $PMGM
    Blank Checks
    Finance

    $PMGM
    SEC Filings

    View All

    SEC Form NT 10-Q filed by Priveterra Acquisition Corp. II

    NT 10-Q - Priveterra Acquisition Corp. II (0001821606) (Filer)

    5/16/24 6:02:05 AM ET
    $PMGM
    Blank Checks
    Finance

    Priveterra Acquisition Corp. II filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - Priveterra Acquisition Corp. II (0001821606) (Filer)

    5/3/24 4:01:08 PM ET
    $PMGM
    Blank Checks
    Finance

    SEC Form NT 10-K filed by Priveterra Acquisition Corp. II

    NT 10-K - Priveterra Acquisition Corp. II (0001821606) (Filer)

    4/2/24 4:05:29 PM ET
    $PMGM
    Blank Checks
    Finance

    $PMGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Priveterra Acquisition Corp. II

    SC 13G - AEON Biopharma, Inc. (0001837607) (Subject)

    2/14/24 1:46:36 PM ET
    $PMGM
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Priveterra Acquisition Corp. II (Amendment)

    SC 13G/A - AEON Biopharma, Inc. (0001837607) (Subject)

    2/14/24 9:00:10 AM ET
    $PMGM
    Blank Checks
    Finance

    SEC Form SC 13D/A filed by Priveterra Acquisition Corp. (Amendment)

    SC 13D/A - AEON Biopharma, Inc. (0001837607) (Subject)

    8/22/23 4:37:53 PM ET
    $PMGM
    Blank Checks
    Finance